Holen Sie sich die Stockscreener-App
20.67
0.39%
0.08
Handel nachbörslich:
20.67
Schlusskurs vom Vortag:
$20.59
Offen:
$20.64
24-Stunden-Volumen:
1.30M
Relative Volume:
1.37
Marktkapitalisierung:
$13.13B
Einnahmen:
$2.75B
Nettoeinkommen (Verlust:
$799.51M
KGV:
20.62
EPS:
1.0022
Netto-Cashflow:
$940.04M
1W Leistung:
-10.91%
1M Leistung:
-10.05%
6M Leistung:
-31.05%
1J Leistung:
-36.98%
1-Tages-Spanne:
$20.58
$20.84
1-Wochen-Bereich:
$20.50
$22.94
52-Wochen-Spanne:
$20.50
$32.88
Genmab Adr Stock (GMAB) Company Profile
Vergleichen Sie GMAB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| GMAB | 20.67 | 13.13B | 2.75B | 799.51M | 940.04M | 1.0022 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Genmab Adr Stock (GMAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-02-23 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2024-01-22 | Herabstufung | Citigroup | Neutral → Sell |
| 2023-12-06 | Hochstufung | UBS | Neutral → Buy |
| 2023-11-10 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2023-11-08 | Hochstufung | DNB Markets | Sell → Buy |
| 2023-10-18 | Eingeleitet | Exane BNP Paribas | Underperform |
| 2023-09-06 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-24 | Eingeleitet | BTIG Research | Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-05-31 | Eingeleitet | UBS | Neutral |
| 2023-05-12 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-12-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-11-14 | Eingeleitet | William Blair | Mkt Perform |
| 2022-11-11 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2022-05-02 | Eingeleitet | Cowen | Market Perform |
| 2022-03-16 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-31 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-12-01 | Eingeleitet | Berenberg | Sell |
| 2021-09-16 | Herabstufung | Jefferies | Buy → Hold |
| 2021-09-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-08-24 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-04-20 | Eingeleitet | Deutsche Bank | Buy |
| 2021-01-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-09-23 | Herabstufung | Bryan Garnier | Neutral → Sell |
| 2020-09-08 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-06-25 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2020-04-23 | Eingeleitet | Credit Suisse | Outperform |
| 2020-02-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-12-12 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2019-09-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-09-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-08-12 | Eingeleitet | Guggenheim | Buy |
| 2019-08-12 | Eingeleitet | Morgan Stanley | Overweight |
| 2019-08-12 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Genmab Adr Aktie (GMAB) Neueste Nachrichten
Weekly Upgrades and Downgrades - InvestorPlace
Genmab to Present at Jefferies London Healthcare Conference - GlobeNewswire Inc.
Is the Options Market Predicting a Spike in Genmab (GMAB) Stock? - Yahoo Finance
Is Genmab (GMAB) Stock Undervalued Right Now? - Yahoo Finance
GMAB or INCY: Which Is the Better Value Stock Right Now? - Yahoo Finance
Down -14.68% in 4 Weeks, Here's Why Genmab (GMAB) Looks Ripe for a Turnaround - Yahoo Finance
Market Resilience: Genmab ADR (GMAB) Finishes Weak at 24.14, Down -5.44 - The Dwinnex
GANDHIM.APPL Share Price Today Up 13% - Equitymaster
Glenmark Pharma Share Price Today Down 3% - Equitymaster
Post-Trade Analysis: Genmab ADR (GMAB) Climbs 1.55, Closing at 26.90 - The Dwinnex
Market Recap: Genmab ADR (GMAB)’s Negative Momentum, Closing at 27.41 - The Dwinnex
All You Need to Know About Genmab (GMAB) Rating Upgrade to Strong Buy - MSN
Wall Street Analysts Think Genmab (GMAB) Could Surge 45.08%: Read This Before Placing a Bet - Yahoo Finance
GMAB vs. CSLLY: Which Stock Is the Better Value Option? - Yahoo Finance
GMAB’s Stock Journey: What Investors Need to Know About Genmab ADR’s Performance - The InvestChronicle
Wall Street Analysts Believe Genmab (GMAB) Could Rally 52.33%: Here's is How to Trade - Zacks Investment Research
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2024 - GlobeNewswire Inc.
ISS suggest Enhabit shareholders elect three AREX Capital nominees to board By Reuters - Investing.com
Antibody Drug Conjugates Market Insights 2018-2023 and - GlobeNewswire Inc.
AbbVie (ABBV) Up 24% in a Year: Buy, Sell or Hold the Stock? - Zacks Investment Research
GMAB or TECH: Which Is the Better Value Stock Right Now? - Yahoo Finance
GMAB vs. TECH: Which Stock Is the Better Value Option? - Yahoo Finance
PBYI vs. GMAB: Which Stock Should Value Investors Buy Now? - Yahoo Canada Shine On
Zacks.com featured highlights include Tap Genmab, KnowBe4, UserTesting, Enphase Energy and Gartner - Yahoo Lifestyle UK
Genmab (GMAB), AbbVie Lymphoma Candidate Gets Orphan Drug Tag - Yahoo Sport Australia
Zacks.com featured highlights Genmab, Hologic, ServiceNow and Splunk - Yahoo New Zealand News
Oncolytics Biotech Inc. (ONCY) Hit a 52 Week High, Can the Run Continue? - Yahoo New Zealand News
FDA Expands AbbVie's (ABBV) Epkinly Label in Follicular Lymphoma - Yahoo Finance
AbbVie (ABBV) BLA for Epcoritamab Gets FDA Priority Tag - Yahoo New Zealand News
GILD or GMAB: Which Is the Better Value Stock Right Now? - Yahoo New Zealand News
Genmab A/S executes share buyback program - Investing.com India
Genmab advances share buy-back program - Investing.com India
Ratio Revelations: Genmab ADR (GMAB)'s Financial Metrics in the Spotlight – DWinneX - The Dwinnex
Truist Securities ups Genmab shares target By Investing.com - Investing.com
AbbVie (ABBV) Signs New Cancer/Immunology Deal With Frontier - Yahoo Lifestyle UK
Genmab ADR (GMAB)'s stock chart: A technical perspective – US Post News - US Post News
Genmab ADR (GMAB) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - The InvestChronicle
Genmab completes $1.8 billion acquisition of ProfoundBio By Investing.com - Investing.com
Genmab AS Sponsored ADR (GMAB) Hits Fresh High: Is There Still Room to Run? - Yahoo Singapore News
Is Genmab (GMAB) Outperforming Other Medical Stocks This Year? - Yahoo Lifestyle UK
Is Elevance Health, Inc. (ELV) Stock Outpacing Its Medical Peers This Year? - Yahoo Singapore News
500: Something went wrong - Investing.com
Genmab Announces Financial Results for the First Quarter of 2024 | GlobeNewswire by notified - NTB Kommunikasjon
Earnings call: Genmab reports strong Q1 growth, plans ProfoundBio acquisition - Investing.com
GMAB: 3 Biotech Stocks Gaining Altitude and Interest - StockNews.com
Genmab's 'Evolution' Continues With A $1.8 Billion Deal; But Shares Slip - Investor's Business Daily
Finanzdaten der Genmab Adr-Aktie (GMAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):